Evidence map›Paper›PMID 28316827›Full record

ArticleActa crystallographica. Section E, Crystallographic communications2017

Crystal structure of 6,7-dimeth-oxy-1-(4-nitro-phen-yl)quinolin-4(1

Vegard Torp Lien, Dag Erlend Olberg, Jo Klaveness, Carl Henrik Görbitz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta crystallographica. Section E, Crystallographic communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Vegard Torp LienDepartment of Pharmaceutical Chemistry, University of Oslo, PO Box 1068 Blindern, N-0371 Oslo, Norway.
Dag Erlend OlbergDepartment of Pharmaceutical Chemistry, University of Oslo, PO Box 1068 Blindern, N-0371 Oslo, Norway.
Jo KlavenessDepartment of Pharmaceutical Chemistry, University of Oslo, PO Box 1068 Blindern, N-0371 Oslo, Norway.
Carl Henrik GörbitzDepartment of Chemistry, University of Oslo, PO Box 1033 Blindern, N-0315 Oslo, Norway.
University of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The protein tubulin is central for maintaining normal cellular processes, and mol-ecules inter-fering with the tubulin dynamics have potential in the treatment of cancerous diseases. The title compound, C

Indexed as

crystal structurecytotoxic agentshydrogen bondingN-substituted quinolonetubulin polymerization

Identifiers

PMID28316827
PMCPMC5347072
OpenAlexW2590497515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.